Resolution Therapeutics names new CFO and CBO

Resolution Therapeutics, a clinical-stage biopharmaceutical company, appointed Lucy Singah as Chief Financial Officer and Daniel Kennedy as Chief Business Officer, according to a company statement.

Singah brings over 20 years of corporate and strategic finance experience from UK and US companies. She previously served as CFO at Echopoint Medical and held various roles at GSK for 11 years, including positions in M&A and investor relations. She also worked at Amazonia Impact Ventures and Axis Spine Technologies. Singah trained as a Chartered Accountant at EY.

Kennedy has more than 20 years of business development experience in pharmaceutical and biotech sectors. He previously worked as Vice President of Business Development at Immunocore plc (NASDAQ: IMCR) and led business development at Achillion Pharmaceuticals before its $930 million acquisition by Alexion Pharmaceuticals (NASDAQ: ALXN), with an additional $300 million in contingent value rights. Kennedy also held positions at Schering-Plough and GSK.

The appointments follow Resolution's recent announcement that the first patient was dosed in its Phase I/II EMERALD study for RTX001, an engineered autologous regenerative macrophage therapy designed to treat inflammatory and fibrotic diseases.

Dr. Amir Hefni, CEO of Resolution Therapeutics, said the company was pleased to welcome both executives to the leadership team during this stage of the company's development.

Resolution Therapeutics is based in Edinburgh and London and focuses on developing regenerative macrophage therapies. The company's lead product, RTX001, is being tested for end-stage liver disease treatment in the EMERALD study.

The company plans to host an R&D webinar on September 17, 2025.

You May Also Be Interested In